Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

About this update from Vivos Therapeutics, Inc.

LITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA") and insomnia, today announced that it has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC ("SPCVA"), a growing Florida-based cardiology practice with approximately 30,000 patients of record, to support the formation and operation of AIM Florida, LLC ("AIM Florida"), a physician-aligned management services organization intended to expand access to integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease (“CVD”) patients in Florida who also suffer from OSA and insomnia. R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos said, "We believe this key collaboration agreement with SPCVA represents a unique and highly profitable model for creating additional such relationships across multiple medical specialties throughout the country. It is based on our current successful model that we have established as a result of our 2025 acquisition of Sleep Centers of Nevada. The key difference here is that we are partnering directly with the medical community without incurring the significant capital outlays required in an acquisition. By creating a true collaboration with fully aligned interests, all parties expect to raise the standard of care for patients who suffer from both OSA and CVD. By aligning our technology and services platform with an experienced Florida cardiology group, we believe AIM Florida can create a scalable, compliant model for expanding access to comprehensive sleep and breathing health solutions throughout the state of Florida, and eventually to the more than 2,500 similar cardiology groups throughout the country." The collaboration will address the key concerns that SPCVA cardiologists have experienced with patients who have some form of CVD along with OSA. Obstructive sleep apnea is independently associated with an increased risk of cardiovascular events and all-cause mortality, particularly among patients with moderate-to-severe disease. Moreover, SPCVA cardiologists report that obtain...

View stock analysis, news, and events for Vivos Therapeutics, Inc.